Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.

Wiegmans, AP; Ivanova, E; Naei, VY; Monkman, J; Fletcher, J; Mullally, W; Warkiani, ME; O'Byrne, K; Kulasinghe, A

Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.

Wiegmans, AP Ivanova, E Naei, VY Monkman, J Fletcher, J Mullally, W Warkiani, ME O'Byrne, K Kulasinghe, A

Permalink

Publisher:: SPRINGER
Publication Type:: Journal Article
Citation:: Clin Exp Metastasis, 2024, 41, (3), pp. 219-228
Issue Date:: 2024-06

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (1.05 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Wiegmans, AP
dc.contributor.author	Ivanova, E
dc.contributor.author	Naei, VY
dc.contributor.author	Monkman, J
dc.contributor.author	Fletcher, J
dc.contributor.author	Mullally, W
dc.contributor.author	Warkiani, ME
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2025-04-03T05:56:12Z
dc.date.available	2024-01-18
dc.date.available	2025-04-03T05:56:12Z
dc.date.issued	2024-06
dc.identifier.citation	Clin Exp Metastasis, 2024, 41, (3), pp. 219-228
dc.identifier.issn	0262-0898
dc.identifier.issn	1573-7276
dc.identifier.uri	http://hdl.handle.net/10453/186559
dc.description.abstract	High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER
dc.relation.ispartof	Clin Exp Metastasis
dc.relation.isbasedon	10.1007/s10585-024-10270-w
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Keratins
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Monocytes
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Biomarkers, Tumor
dc.subject.mesh	Prognosis
dc.subject.mesh	Liquid Biopsy
dc.subject.mesh	Immune Checkpoint Inhibitors
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Adult
dc.subject.mesh	Monocytes
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Prognosis
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Keratins
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Biomarkers, Tumor
dc.subject.mesh	Liquid Biopsy
dc.subject.mesh	Immune Checkpoint Inhibitors
dc.subject.mesh	Humans
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Neoplastic Cells, Circulating
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Keratins
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Monocytes
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Biomarkers, Tumor
dc.subject.mesh	Prognosis
dc.subject.mesh	Liquid Biopsy
dc.subject.mesh	Immune Checkpoint Inhibitors
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Adult
dc.title	Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer.
dc.type	Journal Article
utslib.citation.volume	41
utslib.location.activity	Netherlands
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Health Technologies (CHT)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Institute of Biomedical Materials and Devices (IBMD)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Institute of Biomedical Materials and Devices (IBMD)/Institute of Biomedical Materials and Devices (IBMD) Associate Members
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2025-04-03T05:56:10Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	41
utslib.citation.issue	3

Abstract:

High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells. A stable liquid biopsy biomarker for non-small cell lung cancer lung cancer has yet to be approved for clinical use. We performed a cross-sectional single-site study, and collected liquid biopsies from patients diagnosed with early, locally advanced, or metastatic lung cancer, undergoing surgery, or systemic therapy (chemotherapy/checkpoint inhibitors). Evaluation of overall circulating tumour cell counts, or cluster counts did not correlate with patient outcome. Interestingly, the numbers of Pan cytokeratin positive circulating tumour cells engulfed by tumour associated monocytes correlated strongly with patient outcome independent of circulating tumour cell counts and the use of checkpoint inhibitors. We suggest that Pan cytokeratin staining within monocytes is an important indicator of tumour-associated inflammation post-therapy and an effective biomarker with strong prognostic capability for patient outcome.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/186559